{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-049967","form_type":"8-K","ticker":"OSRH","cik":"0001840425","company_name":"OSR Holdings, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.088611+00:00","generated_at":"2026-05-15T01:05:32.017386+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"OSR Holdings signs $815M VXM01 license with BCM Europe; largest shareholder pledges entire stake as collateral","bullets":["Up to $815M in milestone payments from BCM Europe for VXM01 oral immunotherapy platform (Phase 3-ready VEGFR-2 target).","BCM Europe pledges its entire 9,974,728 shares (~29.7% of OSRH) as collateral for milestone obligations; pledge effective Feb 2028.","OSRH to acquire full VXM01 IP from Vaximm AG for $30M via separate asset purchase agreement.","OSRH receives $15M equity put option at $10/share, exercisable after six months post-effective date.","All downstream royalties after BCME recovers investment and preferred return flow to OSRH."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-049967","json":"https://secwatch.observer/filing/0001213900-26-049967.json","markdown":"https://secwatch.observer/filing/0001213900-26-049967.md","text":"https://secwatch.observer/filing/0001213900-26-049967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/ea0288465-8k_osrhold.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:05:32.017386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90de46d6f5719e4999c930c75ce8e6e3e50c020d","claim":"OSR Holdings, Inc. entered into License Agreement with BCM Europe AG valued at up to $815,000,000 (effective 2026-04-29).","evidence_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-053524","ticker":"HOVR","company_name":"New Horizon Aircraft Ltd.","filed_at":"2026-05-08T23:59:59+00:00","headline":"New Horizon Aircraft raises ~$20M in registered direct offering of 9.25M shares at $2.15","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053524","json":"https://secwatch.observer/filing/0001213900-26-053524.json","markdown":"https://secwatch.observer/filing/0001213900-26-053524.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/0001213900-26-053524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/ea0289712-8k_newhorizon.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"On May 6, 2026, New Horizon Aircraft Ltd. (the “Company”) entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Offering”) an aggregate of 9,254,889 our Class A ordinary shares, without par value (the “Shares\", and each Class A ordinary share with no par value in the authorized share structure of the Company, a “Common Share”). The offering price per Share is $2.15, for aggregate gross proceeds to the Company from the Offering of approximately $19.9 million","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/0001213900-26-053524-index.htm"}},{"accession":"0001104659-26-056482","ticker":"AVTX","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31","event_type":"other_material","sec_items":["1.01","2.02","7.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-056482","json":"https://secwatch.observer/filing/0001104659-26-056482.json","markdown":"https://secwatch.observer/filing/0001104659-26-056482.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001104659-26-057460","ticker":"CLRB","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data","event_type":"other_material","sec_items":["1.01","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057460","json":"https://secwatch.observer/filing/0001104659-26-057460.json","markdown":"https://secwatch.observer/filing/0001104659-26-057460.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/tm2613728d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm"}},{"accession":"0001104659-26-057915","ticker":"SUJA","company_name":"SUJA LIFE, INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026","event_type":"other_material","sec_items":["1.01","3.02","3.03","5.03","5.02","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057915","json":"https://secwatch.observer/filing/0001104659-26-057915.json","markdown":"https://secwatch.observer/filing/0001104659-26-057915.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/0001104659-26-057915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/tm2530822d27_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"On May 6, 2026, Suja Life, Inc. (the “Company”) and Suja Life Holdings, L.P. (“Holdings LP”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) relating to the initial public offering (the “IPO”) of the Company’s Class A common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/0001104659-26-057915-index.htm"}},{"accession":"0001104659-26-057976","ticker":"XRN","company_name":"Chiron Real Estate Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057976","json":"https://secwatch.observer/filing/0001104659-26-057976.json","markdown":"https://secwatch.observer/filing/0001104659-26-057976.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/0001104659-26-057976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/tm2613926d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/0001104659-26-057976-index.htm"}},{"accession":"0001193125-26-214976","ticker":"NKTR","company_name":"NEKTAR THERAPEUTICS","filed_at":"2026-05-08T23:59:59+00:00","headline":"Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO","event_type":"other_material","sec_items":["1.01","5.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214976","json":"https://secwatch.observer/filing/0001193125-26-214976.json","markdown":"https://secwatch.observer/filing/0001193125-26-214976.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm"}},{"accession":"0001493152-26-022034","ticker":"AREB","company_name":"AMERICAN REBEL HOLDINGS INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"American Rebel exchanges $1.77M preferred & note for ~5.97M common shares to Streeterville","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022034","json":"https://secwatch.observer/filing/0001493152-26-022034.json","markdown":"https://secwatch.observer/filing/0001493152-26-022034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/0001493152-26-022034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”),\ntogether with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm","comparable_excerpt":"Streeterville\nSeries E Preferred Exchange Agreements On\nApril 30, 2026, the Company entered into three Exchange Agreements (the “Exchanges”) with Streeterville.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/0001493152-26-022034-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}